此次是自2025年5月以来，再次有被中国扣留的日本人的实刑判决生效。上海市的法院同年5月对一名50 多岁的日本男性以间谍活动的罪名作出有期徒刑12年的有罪判决。该男子也未上诉。 中国政府自2014年11月实施《反间谍法》以来，至少扣留了17名日本人。其中包括安斯泰来男性员工在 内的5人尚未获释。除安斯泰来员工之外的其他4人分别被判处12至15年的有期徒刑，目前正在服刑中。 中国领导层重视"国家安全"，正加强对间谍的打击力度。2023年7月实施了扩大间谍行为定义的新修订 的《反间谍法》，开始广泛查处涉及"国家安全和利益"的信息提供等。 日本政府相关人士透露，该男子利用了坦白罪行可减轻刑罚的事实上的"司法交易"制度。这是中国2018 年10月颁布新修订的《刑事诉讼法》后开始实施的制度。据称，在中国政府以《反间谍法》扣留的日本 人中，该男子是第一个接受司法交易的人。 7月28日，日本驻华大使馆就中国扣留日本人发表声明称"这是阻碍日中间人员往来和国民感情改善的最 大因素之一"。同时表示，将继续向中方寻求提高司法程序的透明度、尽早释放包括安斯泰来员工在内 的被扣日本人。 此次获刑的日本籍男子是安斯泰来制药的中国当地法人 ...

接受采访的日本驻华大使金杉宪治（7月16日，北京，kyodo） 安斯泰来制药的该日籍员工16日被中国法院一审判处有期徒刑 3 年 6 个月。如在 7 月下旬的期限前未提 出上诉，判决即告生效，刑期确定…… 日本经济新闻（中文版：日经中文网）田岛如生 北京报道 相关报道： 安斯泰来日籍员工在中国被判3年6个月 版权声明：日本经济新闻社版权所有，未经授权不得转载或部分复制，违者必究。 日经中文网 https://cn.nikkei.com 据中日相关消息人士透露，因被控在中国从事 " 间谍活动 " 而于 7 月 16 日被中国法院一审判处有期徒 刑 3 年 6 个月的安斯泰来制药 60 多岁日本籍男性员工将不提出上诉。 中国实行二审终审制，被告如对一审判决不服，有权提出上诉。中国《刑事诉讼法》规定，被告必须在 判决次日起 10 日内决定是否上诉。本案被告如在 7 月下旬的期限前未提出上诉，判决即告生效，刑期 确定。 北京第二中级人民法院（地方法院）于 7 月 16 日对该男性作出实刑判决。据旁听庭审的日本驻华大使 金杉宪治表示，法院虽提及了 " 间谍活动 " 的内容，但对犯罪的构成要件以及是否存在故意并未作出具 ...

Group 1 - Japanese companies are increasingly cautious about investing in China due to the risk of employee detentions, with at least 17 Japanese nationals detained in the past decade [1][2] - Following the detention of an employee from Astellas Pharma in March 2023, Japanese firms have implemented emergency measures, including avoiding unnecessary business trips to China [1][2] - The attitude of Japanese companies has shifted from "blind fear" to "rational vigilance," as they develop self-protection strategies for employees traveling to China [1][2] Group 2 - Since the implementation of China's Anti-Espionage Law in 2014, the scrutiny of foreigners has intensified, leading to a significant decline in direct investment from Japan to China, with net investment dropping by 63% over three years [2] - A survey by the Japan External Trade Organization (JETRO) in 2024 revealed that only 33% of Japanese companies are considering expanding or starting new businesses in China, the lowest level since 2013 [2] Group 3 - Concerns about safety in China have risen among Japanese nationals, with a notable decline in the number of Japanese residents in China, falling below 100,000 for the first time in 20 years [3] - Incidents involving foreign nationals, including the detention of employees from Mintz Group and a South Korean individual, highlight ongoing risks for expatriates in China [3]

安斯泰来制药（资料图） 当天出席公开宣判并旁听的日本驻中国大使金杉宪治在北京市内向媒体披露了相关消息， 金 杉表示："对此次的有罪判决，我们深感遗憾"。据统计，自2014年以来，已有至少17名日本 人在中国被扣留，目前仍有5人未获释放，其中4人已被判刑并在服刑中…… 7月16日，中国北京市第二中级人民法院对被以间谍罪起诉的日本安斯泰来制药的60多岁日 籍男性员工做出有罪判决，判处有期徒刑3年6个月。 中国有关部门于2023年3月，在该男子即将结束驻华任期准备返回日本之际，于北京市内将 其扣留。中国的检察机关于2024年8月以间谍罪对该男子提起公诉，但但并未公布起诉的具 体内容。首次公开庭审于2024年11月举行。 该男子曾任安斯泰来制药中国当地法人高管，累计驻华时间超过20年，并曾担任由进驻当地 的日本企业组成的"中国日本商会"的副会长。自2023年3月被扣以来，日本政府多次由金杉 大使等人进行领事探视。 中国实行两审终审制，当事人对一审判决不服可以提出上诉。 此前，在2025年5月，上海市的法院曾以间谍罪判处一名50多岁的日本男性有期徒刑12年， 该名男子未提出上诉。 据统计，自2014年以来，已有至少17 ...

Group 1 - Alpha Cognition Inc. (ACOG) is currently ranked 7 in the Zacks Sector Rank among 989 companies in the Medical group, indicating strong performance relative to peers [2] - ACOG has a Zacks Rank of 1 (Strong Buy), suggesting it is poised to outperform the broader market in the next one to three months [3] - Over the past three months, the Zacks Consensus Estimate for ACOG's full-year earnings has increased by 49.3%, reflecting improved analyst sentiment and a positive earnings outlook [4] Group 2 - Year-to-date, ACOG has gained approximately 58.4%, while the average performance of Medical group stocks has declined by about 3.7%, demonstrating ACOG's strong outperformance [4] - ACOG belongs to the Medical - Biomedical and Genetics industry, which includes 497 companies and is currently ranked 85 in the Zacks Industry Rank; this industry has seen an average loss of 3.4% this year, further highlighting ACOG's superior performance [6] - Astellas Pharma Inc. (ALPMY), another stock in the Medical sector, has a year-to-date return of 0.9% and a Zacks Rank of 1 (Strong Buy), with its EPS consensus estimate increasing by 15.2% over the past three months [5][6]

Company Overview - Astellas Pharma Inc. (ALPMY) is a notable stock in the Medical sector, which consists of 998 individual stocks and ranks 6 in the Zacks Sector Rank [2] - The company currently holds a Zacks Rank of 1 (Strong Buy), indicating strong potential for outperforming the market in the near term [3] Performance Analysis - Astellas Pharma's full-year earnings consensus estimate has increased by 15.3% over the past quarter, reflecting improved analyst sentiment and earnings outlook [4] - Year-to-date, Astellas Pharma has gained approximately 1%, while the average loss in the Medical group is about 2.4%, showcasing its better performance relative to the sector [4] Industry Context - Astellas Pharma belongs to the Medical - Drugs industry, which includes 164 companies and currently ranks 71 in the Zacks Industry Rank [6] - The Medical - Drugs industry has seen an average gain of 3% year-to-date, indicating that Astellas Pharma is slightly underperforming its industry peers [6] Comparative Analysis - Another stock, AtriCure (ATRC), has outperformed the sector with an 8.1% gain year-to-date and has a Zacks Rank of 2 (Buy) [5] - AtriCure is part of the Medical - Products industry, which has 83 stocks and ranks 140, with an average gain of 5.7% since the beginning of the year [7]

Core Insights - Astellas Pharma has entered into an exclusive license agreement with Evopoint Biosciences for the development and commercialization of XNW27011, a novel investigational antibody-drug conjugate targeting CLDN18.2, with worldwide rights excluding certain regions in China [1][3][6] Group 1: Agreement Details - The agreement grants Astellas exclusive worldwide rights (excluding mainland China, Hong Kong, Macao, and Taiwan) to develop and commercialize XNW27011 [1] - Evopoint will receive a $130 million upfront payment and is eligible for up to $70 million in near-term payments, with additional milestone payments totaling up to $1.34 billion, plus royalties on net sales if approved [1][4] Group 2: Clinical Development - XNW27011 is currently being evaluated in a Phase 1/2 study in China for patients with CLDN18.2-expressing solid tumors, including gastric cancer, gastroesophageal cancer, and pancreatic cancer [2][3] - The drug utilizes a proprietary topoisomerase I inhibitor payload and linker technology, which has shown clinical success in other approved cancer therapies [2] Group 3: Strategic Importance - Astellas has significant expertise in developing therapies targeting CLDN18.2, including VYLOYTM, the first CLDN18.2-targeted therapy approved globally [3] - The addition of XNW27011 is expected to address unmet patient needs and expand Astellas' oncology pipeline, which includes various CLDN-targeting therapies and ADCs directed at other targets [3][5]

Core Insights - The ARCHES trial's five-year follow-up data indicates that enzalutamide combined with androgen deprivation therapy (ADT) reduces the risk of death by 30% in patients with metastatic hormone-sensitive prostate cancer (mHSPC) [1][2] - The five-year survival rate for patients receiving enzalutamide with ADT is 66%, compared to 53% for the placebo group [1] - Enzalutamide is the first and only androgen receptor inhibitor to demonstrate a five-year overall survival benefit in mHSPC patients [1] Group 1: Clinical Efficacy - The five-year follow-up shows a 13% absolute increase in survival rate compared to standard hormone therapy, with a relative survival improvement of 30% [2] - Significant clinical benefits were observed across various patient subgroups, including those with high tumor burden and those who had not previously received docetaxel treatment [2] - In high tumor burden patients, the median overall survival (OS) improved by 36 months [2] Group 2: Safety and Tolerability - The incidence of adverse events during treatment was consistent with previous ARCHES analyses, with no new safety signals identified [2] Group 3: Research and Development - The five-year results from the ARCHES study will be presented at the American Society of Clinical Oncology (ASCO) annual meeting [1] - Additional data from the ENZAMET study, which evaluates enzalutamide versus non-steroidal anti-androgens (NSAA) in mHSPC, will also be showcased [3][4] Group 4: Market Position - Enzalutamide has been approved in over 90 countries, with more than 1 million patients treated globally since its first approval in 2012 [5] - The ongoing research and accumulating data further solidify enzalutamide's long-term efficacy and patient benefits in advanced prostate cancer treatment [3][4]

Company Overview - Astellas Pharma Inc. is part of the Medical sector, which includes 997 individual stocks and currently holds a Zacks Sector Rank of 4 [2] - The company is classified under the Medical - Drugs industry, which consists of 161 companies and is ranked 52 in the Zacks Industry Rank [6] Performance Analysis - Astellas Pharma Inc. has a Zacks Rank of 1 (Strong Buy), indicating a positive outlook based on earnings estimates and revisions [3] - Over the past 90 days, the Zacks Consensus Estimate for Astellas Pharma's full-year earnings has increased by 20.7%, reflecting improved analyst sentiment [4] - Year-to-date, Astellas Pharma has returned approximately 0.3%, outperforming the Medical sector, which has seen an average loss of 7.1% [4] Comparative Analysis - AtriCure, another stock in the Medical sector, has a year-to-date return of 7% and a Zacks Rank of 2 (Buy) [5] - The Medical - Products industry, where AtriCure is categorized, has a ranking of 147 and has increased by 3.8% since the beginning of the year [7] - In contrast, Astellas Pharma's industry has underperformed slightly, with an average loss of 2% year-to-date [6]

Core Viewpoint - Astellas Pharma Inc. (ALPMY) has experienced a 7% decline in shares over the past week, but the formation of a hammer chart pattern suggests potential support and a possible trend reversal in the future [1][2]. Technical Analysis - The hammer chart pattern indicates a potential bottoming out, with selling pressure likely subsiding, which supports a bullish outlook for the stock [2][5]. - A hammer pattern typically forms during a downtrend, where the stock opens lower, makes a new low, but then closes near or above the opening price, indicating buying interest [4][5]. - The effectiveness of the hammer pattern is contingent on its placement on the chart and should be used alongside other bullish indicators [6]. Fundamental Analysis - There has been a recent upward trend in earnings estimate revisions for ALPMY, which is a bullish indicator suggesting potential price appreciation [7]. - The consensus EPS estimate for the current year has increased by 9.9% over the last 30 days, indicating strong agreement among analysts regarding improved earnings potential [8]. - ALPMY holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks, which typically outperform the market [9].